Microbot Medical Inc. (Nasdaq: MBOT), developer and distributor of the LIBERTY® Endovascular Robotic System, has entered into an agreement with Lovell® Government Services to serve federal healthcare systems. This partnership aims to expand the company's reach into critical government-managed medical facilities, including the Veterans Health Administration (VHA), the Military Health System (MHS), and the U.S. Indian Health Service (IHS). The collaboration leverages Lovell Government Services' status as a Service-Disabled Veteran-Owned Small Business (SDVOSB) vendor to navigate federal contracting systems effectively.

The agreement positions Microbot Medical to provide its robotic surgical technology to the VHA, a division of the U.S. Department of Veteran Affairs. It also targets the MHS, operated by the U.S. Department of Defense, and the IHS. By utilizing Lovell Government Services as its designated SDVOSB vendor, Microbot Medical intends to streamline its entry into these regulated markets.

Lovell Government Services has been an SDVOSB vendor since 2013 and is a four-time Inc. 5000 honoree. Microbot Medical's LIBERTY System will be added to Lovell's Federal Supply Schedule (FSS) contract, with activation expected during the third quarter of 2026. The system will also be accessible through additional federal procurement platforms, including GSA Advantage, the Defense Logistics Agency's Electronic Catalog (ECAT), and the Department of Defense's Distribution and Pricing Agreement (DAPA).

Key Partnership Details

The strategic agreement outlines the roles of both entities in delivering advanced medical solutions to federal healthcare providers.

Lovell serves thousands of government care sites nationwide, including 170 medical centers and numerous outpatient clinics, averaging over 200 peripheral endovascular cases annually per site. Listing products with Lovell is expected to streamline the sales process while helping government agencies meet their SDVOSB procurement goals.

Microbot Medical Inc. has secured the first adoption of its LIBERTY Endovascular Robotic System in Michigan, expanding its footprint across the Midwest U.S. region. A major health system in Michigan, recognized as one of the largest in the state, has implemented the technology, marking a significant step in the company's commercialization efforts. This development follows a recent announcement regarding the system's first healthcare system customer in North Carolina, reinforcing growing interest among health systems in advanced robotic solutions.

The company attributes this progress to increasing demand for robotic assistance in peripheral endovascular procedures and a rising readiness among major health systems to integrate such technologies into routine vascular care. Microbot Medical views these adoptions as validation of its recent transition to full market release in the U.S. The U.S. market for peripheral endovascular procedures encompasses approximately 2.5 million procedures annually, representing a substantial commercial opportunity.

Harel Gadot, Chairman, President & CEO of Microbot Medical, highlighted the strategic importance of these expansions. He stated that the addition of new healthcare system customers reflects growing recognition that robotics can be delivered in a practical and accessible manner. Gadot noted increasing interest from physicians and hospital leaders who recognize the system's potential to enhance procedural workflows and support physician well-being, positioning the company for continued growth and market penetration.

The LIBERTY System is distinguished as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures. It is designed for precise vascular navigation with the aim of reducing radiation exposure and physical strain on medical personnel. Recently, the system also received regulatory approval from the Israeli Ministry of Health's AMAR Division, authorizing the company to market and sell the LIBERTY System in Israel.

Key Features of the LIBERTY System